Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;25(14):1835-1841.
doi: 10.1177/1352458519884006. Epub 2019 Nov 5.

Remyelination and ageing: Reversing the ravages of time

Affiliations
Review

Remyelination and ageing: Reversing the ravages of time

Bjoern Neumann et al. Mult Scler. 2019 Dec.

Abstract

Remyelination is a neuroprotective regenerative response to demyelination that restores saltatory conduction and decreases the vulnerability of axons to irreversible degeneration. It is a highly efficient process: however, as with all regenerative processes, its efficiency declines with ageing. Here we argue that this age-related decline in remyelination has a major impact on the natural history of multiple sclerosis (MS), a disease often of several decades' duration. We describe recent work on (1) how ageing changes the function of oligodendrocyte progenitor cells (OPCs), the cells primarily responsible for generating new myelin-forming oligodendrocytes in remyelination, (2) how these changes are induced by age-related changes in the OPC niche and (3) how these changes can be reversed, thereby opening up the possibility of therapeutically maintaining remyelination efficiency throughout the disease, preserving axonal health and treating the progressive phase of MS.

Keywords: Remyelination; ageing; oligodendrocyte progenitor cell; stem cell.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

Figure 1.
Figure 1.
OPCs, like other adult stem cells, undergo functional decline with ageing: they have a diminished ability to self-renew and to differentiate. The dysfunction of aged OPCs is underlined by the acquisition of hallmarks of ageing, like DNA damage and mitochondrial dysfunction. The functional capacity of an OPC is determined by its environment (niche) as OPCs transplanted, irrespective of their own age, function like OPCs of the age of the host tissue (i.e. young or aged OPCs transplanted into a young brain behave like young OPCs). Many biochemical and histological changes that occur in the extracellular environment with ageing have been described, but our recent data demonstrate that the physical properties (stiffness) of the brain play a key role in the ageing process. Interventions, such as heterochronic parabiosis or treatment with metformin, restore a youthful niche and can reinstate the stem cell potential of OPCs and thereby their capacity for remyelination. Alternatively, aged OPCs can be reprogrammed to a more youthful state. The deletion of Piezo 1 prevents OPCs from sensing the stiffness of the niche. Thus, aged OPCs behave as young OPCs that are normally exposed to a soft environment. Therefore, strategies that restore a more youthful environment or that make OPCs impervious to extracellular changes that occur with ageing lead to a functional rejuvenation of OPCs and thereby store the capacity of aged animals for remyelination.

References

    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med 2018; 378(2): 169–180. - PMC - PubMed
    1. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis: Success from bench to bedside. Nat Rev Neurol 2019; 15(1): 53–58. - PubMed
    1. Cuascut FX, Hutton GJ. Stem cell-based therapies for multiple sclerosis: Current perspectives. Biomedicines 2019; 7(2): E26. - PMC - PubMed
    1. Faissner S, Plemel JR, Gold R, et al. Progressive multiple sclerosis: From pathophysiology to therapeutic strategies. Nat Rev Drug Discov 2019; 378(Pt 1): 169–180. - PubMed
    1. Ciotti JR, Cross AH. Disease-modifying treatment in progressive multiple sclerosis. Curr Treat Options Neurol 2018; 20(5): 12. - PubMed

Publication types

MeSH terms